Alkermes PLC Form 4 insider transactions

Alkermes plc Director Christopher I. Wright reported the exercise of restricted stock units and the subsequent sale of shares to cover tax liabilities.

Alkermes plc Director Frank Anders Wilson reported the acquisition of 8,013 ordinary shares through the vesting of restricted stock units and the subsequent disposition of 1,924 shares for tax purposes, resulting in a net increase in his direct beneficial ownership.

Alkermes plc. Director Nancy Lynn Snyderman MD reported the conversion of 8,013 restricted stock units into ordinary shares and the subsequent sale of 1,924 shares to cover tax liabilities.

Alkermes plc Director Brian P. McKeon exercised restricted stock units and sold a portion of the resulting ordinary shares to cover tax withholding obligations.

Alkermes plc Director Nancy Lurker reported the exercise of 8,013 restricted stock units and the subsequent sale of 1,924 ordinary shares to cover tax liabilities, resulting in a net direct ownership of 10,705 shares.

Alkermes plc Director Richard Gaynor has reported the vesting of 8,013 restricted stock units and the subsequent disposition of 1,924 shares for tax withholding purposes, increasing his direct beneficial ownership to 31,084 ordinary shares.

Alkermes plc Director Shane Cooke reported an increase in his direct beneficial ownership of ordinary shares after the vesting of restricted stock units and a subsequent tax-related disposition.

Alkermes plc Director Christopher I. Wright was granted non-qualified stock options and restricted stock units on May 21, 2025, as part of his compensation, aligning his interests with shareholders.

Alkermes plc Director Frank Anders Wilson has reported the acquisition of 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025.

Alkermes plc Director Dr. Nancy Snyderman has reported the acquisition of non-qualified stock options and restricted stock units as part of her compensation.

Alkermes plc Director Brian P. McKeon reported the acquisition of 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025, as part of his beneficial ownership.

Alkermes plc. Director Nancy Lurker was granted non-qualified stock options and restricted stock units as part of her compensation on May 21, 2025.

Alkermes plc Director Cato T. Laurencin was granted 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025, as reported in a recent SEC Form 4 filing.

Alkermes plc Director Richard Gaynor has been granted non-qualified stock options and restricted stock units as part of his compensation, aligning his interests with shareholders.

Alkermes plc Director Shane Cooke was granted 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025, as part of his compensation.

Director Nancy Lurker reports transactions involving Alkermes plc ordinary shares, including the vesting and disposal of restricted stock units.

Samuel Joseph Parisi, VP of Finance (Interim PAO) at Alkermes plc, reported the vesting of restricted stock units, subsequent sale of shares, and tax withholding.

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

EVP, Chief Operating Officer of Alkermes plc, Blair Curtis Jackson, reports acquisition and disposal of ordinary shares and restricted stock units.

Craig Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

David Gaffin, EVP and CLO of Alkermes, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

Iain Michael Brown, CFO of Alkermes plc, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

David Gaffin, EVP, CLO of Alkermes, reports transactions involving ordinary shares and restricted stock units.

EVP and Chief Operating Officer of Alkermes plc, Blair Curtis Jackson, reports transactions involving ordinary shares and restricted stock units.

Alkermes' VP of Finance, Samuel Joseph Parisi, reports the acquisition and disposal of ordinary shares and restricted stock units.

Iain Michael Brown, CFO of Alkermes plc, reports the vesting and subsequent disposal of restricted stock units, resulting in changes to his beneficial ownership of ordinary shares.

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, reports the vesting and subsequent disposal of restricted stock units.

EVP R&D, Chief Medical Officer of Alkermes, Craig C. Hopkinson, reports transactions involving ordinary shares and restricted stock units.

Samuel Joseph Parisi, VP of Finance (Interim PAO) at Alkermes plc, reports transactions involving ordinary shares and derivative securities.

Christian Todd Nichols, SVP, Chief Commercial Officer of Alkermes plc, reports transactions involving ordinary shares and derivative securities, including the vesting of restricted stock units and the grant of new stock options and restricted stock units.